Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 194

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline

Open access
Rosenzweig, James L., Ferrannini, Ele, Grundy, Scott M., Haffner, Steven M., Heine, Robert J., Horton, Edward S., Kawamori, Ryuzo·2008·The Journal of Clinical Endocrinology & Metabolism

Abstract

OBJECTIVE: The objective was to develop clinical practice guidelines for the primary prevention of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) in patients at metabolic risk. CONCLUSIONS: Healthcare providers should incorporate into their practice concrete measures to reduce the risk of developing CVD and T2DM. These include the regular screening and identification of patients at metabolic risk (at higher risk for both CVD and T2DM) with measurement of blood pressure, waist circumference, fasting lipid profile, and fasting glucose. All patients identified as having metabolic risk should undergo 10-yr global risk assessment for either CVD or coronary heart disease. This scoring will determine the targets of therapy for reduction of apolipoprotein B-containing lipoproteins. Careful attention should be given to the treatment of elevated blood pressure to the targets outlined in this guideline. The prothrombotic state associated with metabolic risk should be treated with lifestyle modification measures and in appropriate individuals with low-dose aspirin prophylaxis. Patients with prediabetes (impaired glucose tolerance or impaired fasting glucose) should be screened at 1- to 2-yr intervals for the development of diabetes with either measurement of fasting plasma glucose or a 2-h oral glucose tolerance test. For the prevention of CVD and T2DM, we recommend that priority be given to lifestyle management. This includes antiatherogenic dietary modification, a program of increased physical activity, and weight reduction. Efforts to promote lifestyle modification should be considered an important component of the medical management of patients to reduce the risk of both CVD and T2DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2008-0222

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Research works printed but not linked: 82

  1. 1998, Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report., National Institutes of Health. Obes Res, 6, 51S
  2. Meigs, 2007, Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome., Diabetes Care, 30, 1219, 10.2337/dc06-2484 · DOI · Paper page
  3. Wilson, 2005, Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus., Circulation, 112, 3066, 10.1161/CIRCULATIONAHA.105.539528 · DOI · Paper page
  4. Ferrannini, 1995, Primary insulin resistance: a risk syndrome, In: Leslie RDG, Robbins DC, eds. Diabetes: clinical science in practice. Cambridge, UK: Cambridge University Press;, 200
  5. Rutter, 2005, Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study., Diabetes, 54, 3252, 10.2337/diabetes.54.11.3252 · DOI · Paper page
  6. Tan, 2004, Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?, Diabetes Care, 27, 1182, 10.2337/diacare.27.5.1182 · DOI · Paper page
  7. Ko, 2005, High prevalence of metabolic syndrome in Hong Kong Chinese: comparison of three diagnostic criteria., Diabetes Res Clin Pract, 69, 160, 10.1016/j.diabres.2004.11.015 · DOI
  8. Salmasi, 2004, Prevalence of unrecognized abnormal glucose tolerance in patients attending a hospital hypertension clinic., Am J Hypertens, 17, 483, 10.1016/j.amjhyper.2004.01.011 · DOI
  9. Salmasi, 2005, The glucose tolerance test, but not HbA1c, remains the gold standard in identifying unrecognized diabetes mellitus and impaired glucose tolerance in hypertensive subjects., Angiology, 56, 571, 10.1177/000331970505600508 · DOI
  10. Meigs, 2006, Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease., J Clin Endocrinol Metab, 91, 2906, 10.1210/jc.2006-0594 · DOI · Paper page
  11. Meigs, 2004, Using metabolic syndrome traits for efficient detection of impaired glucose tolerance., Diabetes Care, 27, 1417, 10.2337/diacare.27.6.1417 · DOI
  12. Kothari, 2002, UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine., Stroke, 33, 1776, 10.1161/01.STR.0000020091.07144.C7 · DOI
  13. Folsom, 2006, An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study., Arch Intern Med, 166, 1368, 10.1001/archinte.166.13.1368 · DOI · Paper page
  14. Davey Smith, 2006, C-Reactive protein and cardiovascular disease risk: still an unknown quantity?, Ann Intern Med, 145, 70, 10.7326/0003-4819-145-1-200607040-00130 · DOI
  15. Cui, 2001, Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality., Arch Intern Med, 161, 1413, 10.1001/archinte.161.11.1413 · DOI · Paper page
  16. Jiang, 2004, Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes., Diabetes Care, 27, 1991, 10.2337/diacare.27.8.1991 · DOI · Paper page
  17. Liu, 2005, Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes., Diabetes Care, 28, 1916, 10.2337/diacare.28.8.1916 · DOI · Paper page
  18. Lu, 2003, Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the Strong Heart Study., Diabetes Care, 26, 16, 10.2337/diacare.26.1.16 · DOI · Paper page
  19. Schulze, 2004, Joint role of non-HDL cholesterol and glycated haemoglobin in predicting future coronary heart disease events among women with type 2 diabetes., Diabetologia, 47, 2129, 10.1007/s00125-004-1593-2 · DOI
  20. Simon, 2005, Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men., Atherosclerosis, 179, 339, 10.1016/j.atherosclerosis.2004.10.017 · DOI
  21. Xydakis, 2003, Role of non-high-density lipoprotein cholesterol in prevention of cardiovascular disease: updated evidence from clinical trials., Curr Opin Cardiol, 18, 503, 10.1097/00001573-200311000-00012 · DOI
  22. 1975, Clofibrate and niacin in coronary heart disease., JAMA, 231, 360, 10.1001/jama.1975.03240160024021 · DOI · Paper page
  23. Canner, 2006, Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project)., Am J Cardiol, 97, 477, 10.1016/j.amjcard.2005.08.070 · DOI
  24. Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial., Lancet, 366, 1849, 10.1016/S0140-6736(05)67667-2 · DOI · Paper page
  25. Barter, 2008, Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?, Arterioscler Thromb Vasc Biol, 28, 39, 10.1161/ATVBAHA.107.148817 · DOI
  26. Zambon, 2007, The role of fenofibrate in clinical practice, Diab Vasc Dis Res, 4, S15, 10.3132/dvdr.2007.053 · DOI
  27. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, 2002, Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)., JAMA, 288, 2998, 10.1001/jama.288.23.2998 · DOI · Paper page
  28. Law, 1994, By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?, BMJ, 308, 367, 10.1136/bmj.308.6925.367 · DOI · Paper page
  29. Scandinavian Simvastatin Survival Study Group, 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)., Lancet, 344, 1383
  30. Sever, 2003, Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial., Lancet, 361, 1149, 10.1016/S0140-6736(03)12948-0 · DOI · Paper page
  31. Frost, 1996, Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP)., Circulation, 94, 2381, 10.1161/01.CIR.94.10.2381 · DOI
  32. Pedersen, 2005, High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial., JAMA, 294, 2437, 10.1001/jama.294.19.2437 · DOI · Paper page
  33. Cooper, 2000, Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention., Circulation, 102, 3137, 10.1161/01.CIR.102.25.3137 · DOI · Paper page
  34. Hutchinson, 1997, Racial differences in risk factors for atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities., Angiology, 48, 279, 10.1177/000331979704800401 · DOI
  35. Sprafka, 1992, Life-style factors do not explain racial differences in high-density lipoprotein cholesterol: the Minnesota Heart Survey., Epidemiology, 3, 156, 10.1097/00001648-199203000-00014 · DOI
  36. Fontaine, 2003, Years of life lost due to obesity., JAMA, 289, 187, 10.1001/jama.289.2.187 · DOI · Paper page
  37. Julius, 2004, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial., Lancet, 363, 2022, 10.1016/S0140-6736(04)16451-9 · DOI · Paper page
  38. Julius, 2006, Feasibility of treating prehypertension with an angiotensin-receptor blocker., N Engl J Med, 354, 1685, 10.1056/NEJMoa060838 · DOI · Paper page
  39. Julius, 2006, The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy., Hypertension, 48, 385, 10.1161/01.HYP.0000236119.96301.f2 · DOI
  40. Dahlof, 2002, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol., Lancet, 359, 995, 10.1016/S0140-6736(02)08089-3 · DOI · Paper page
  41. Dahlof, 2005, Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial., Lancet, 366, 895, 10.1016/S0140-6736(05)67185-1 · DOI · Paper page
  42. Black, 2003, Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial., JAMA, 289, 2073, 10.1001/jama.289.16.2073 · DOI · Paper page
  43. Verdecchia, 2005, Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention., Hypertension, 46, 386, 10.1161/01.HYP.0000174591.42889.a2 · DOI · Paper page
  44. Wright Jr, 2002, Successful blood pressure control in the African American Study of Kidney Disease and Hypertension., Arch Intern Med, 162, 1636, 10.1001/archinte.162.14.1636 · DOI
  45. Balagopal, 2005, Lifestyle-only intervention attenuates the inflammatory state associated with obesity: a randomized controlled study in adolescents., J Pediatr, 146, 342, 10.1016/j.jpeds.2004.11.033 · DOI · Paper page
  46. Esposito, 2003, Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial., JAMA, 289, 1799, 10.1001/jama.289.14.1799 · DOI · Paper page
  47. Hamdy, 2003, Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome., Diabetes Care, 26, 2119, 10.2337/diacare.26.7.2119 · DOI · Paper page
  48. Selvin, 2007, The effect of weight loss on C-reactive protein: a systematic review., Arch Intern Med, 167, 31, 10.1001/archinte.167.1.31 · DOI · Paper page
  49. Erdmann, 2007, The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study., J Am Coll Cardiol, 49, 1772, 10.1016/j.jacc.2006.12.048 · DOI · Paper page
  50. Pearson, 2002, AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke. 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee., Circulation, 106, 388, 10.1161/01.CIR.0000020190.45892.75 · DOI · Paper page
  51. Folsom, 1993, Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults., Arterioscler Thromb, 13, 162, 10.1161/01.ATV.13.2.162 · DOI · Paper page
  52. Hamalainen, 2005, Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study., Diabetologia, 48, 2248, 10.1007/s00125-005-1938-5 · DOI
  53. Lindahl, 1999, Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance., J Intern Med, 246, 105, 10.1046/j.1365-2796.1999.00537.x · DOI
  54. Marckmann, 1998, Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects., Eur J Clin Nutr, 52, 329, 10.1038/sj.ejcn.1600558 · DOI
  55. Rissanen, 2001, Weight change and blood coagulability and fibrinolysis in healthy obese women., Int J Obes Relat Metab Disord, 25, 212, 10.1038/sj.ijo.0801540 · DOI
  56. Antithrombotic Trialists’ Collaboration, 2002, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients., BMJ, 324, 71, 10.1136/bmj.324.7329.71 · DOI · Paper page
  57. Hayden, 2002, Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force., Ann Intern Med, 136, 161, 10.7326/0003-4819-136-2-200201150-00016 · DOI · Paper page
  58. Kosaka, 2005, Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males., Diabetes Res Clin Pract, 67, 152, 10.1016/j.diabres.2004.06.010 · DOI · Paper page
  59. Pan, 1997, Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study., Diabetes Care, 20, 537, 10.2337/diacare.20.4.537 · DOI · Paper page
  60. Norris, 2005, Long-term effectiveness of weight-loss interventions in adults with pre-diabetes: a review., Am J Prev Med, 28, 126, 10.1016/j.amepre.2004.08.006 · DOI
  61. Yamaoka, 2005, Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials., Diabetes Care, 28, 2780, 10.2337/diacare.28.11.2780 · DOI · Paper page
  62. Ratner, 2005, Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program., Diabetes Care, 28, 888, 10.2337/diacare.28.4.888 · DOI · Paper page
  63. Haffner, 2005, Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance., Diabetes, 54, 1566, 10.2337/diabetes.54.5.1566 · DOI · Paper page
  64. Elliott, 2002, Fructose, weight gain, and the insulin resistance syndrome., Am J Clin Nutr, 76, 911, 10.1093/ajcn/76.5.911 · DOI · Paper page
  65. Dormandy, 2005, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial., Lancet, 366, 1279, 10.1016/S0140-6736(05)67528-9 · DOI · Paper page
  66. Swiglo, 2008, A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the GRADE system., J Clin Endocrinol Metab, 93, 666, 10.1210/jc.2007-1907 · DOI · Paper page
  67. Reaven, 1988, Banting lecture 1988. Role of insulin resistance in human disease., Diabetes, 37, 1595, 10.2337/diab.37.12.1595 · DOI · Paper page
  68. LaMonte, 2005, Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: a prospective study of men and women., Circulation, 112, 505, 10.1161/CIRCULATIONAHA.104.503805 · DOI · Paper page
  69. Bjorntorp, 1995, Insulin resistance: the consequence of a neuroendocrine disturbance, Int J Obes Relat Metab Disord 19 Suppl, 1, S6
  70. Ferrannini, 1995, The phenomenon of insulin resistance: its possible relevance to hypertensive disease, In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press;, 2281
  71. Muscelli, 1998, Autonomic and hemodynamic responses to insulin in lean and obese humans., J Clin Endocrinol Metab, 83, 2084
  72. Ferrannini, 2006, Is insulin resistance the cause of the metabolic syndrome?, Ann Med, 38, 42, 10.1080/07853890500415358 · DOI
  73. Haffner, 1992, Prospective analysis of the insulin-resistance syndrome (syndrome X)., Diabetes, 41, 715, 10.2337/diab.41.6.715 · DOI · Paper page
  74. Haffner, 1992, Clustering of cardiovascular risk factors in confirmed prehypertensive individuals., Hypertension, 20, 38, 10.1161/01.HYP.20.1.38 · DOI · Paper page
  75. Hu, 2004, Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies., Diabetologia, 47, 1245, 10.1007/s00125-004-1433-4 · DOI · Paper page
  76. Ferrannini, 2002, Insulin: in search of a syndrome., Diabet Med, 19, 724, 10.1046/j.1464-5491.2002.00794.x · DOI
  77. Despres, 2006, Is visceral obesity the cause of the metabolic syndrome?, Ann Med, 38, 52, 10.1080/07853890500383895 · DOI · Paper page
  78. Alberti, 1998, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation., Diabet Med, 15, 539, 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s
  79. Lorenzo, 2005, The prevalence of the metabolic syndrome did not increase in Mexico City between 1990–1992 and 1997–1999 despite more central obesity., Diabetes Care, 28, 2480, 10.2337/diacare.28.10.2480 · DOI
  80. Ford, 2005, Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence., Diabetes Care, 28, 1769, 10.2337/diacare.28.7.1769 · DOI · Paper page
  81. Saaristo, 2005, Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome., Diab Vasc Dis Res, 2, 67, 10.3132/dvdr.2005.011 · DOI · Paper page
  82. Kahn, 2005, The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes., Diabetologia, 48, 1684, 10.1007/s00125-005-1876-2 · DOI · Paper page

Cited by

See all 194

Metadata

Authors
Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., & Kawamori, R.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2008-10-01
Volume
93
Issue
10
Pages
3671-3689
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2166693613
Cited by
194
References
60
FWCI
11.77
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline. https://app.cochat.ai/papers/10.1210/jc.2008-0222
The paper
Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., & Kawamori, R. (2008). Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2008-0222

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.